Safety Signals in Phase II While efficacy was impressive, the trials also raised important safety concerns: Heart rate increases: Mean increases of 7.4 bpm (0.5 mg) and 9.1 bpm (1.0 mg) versus placebo Blood pressure: Modest systolic increases at higher doses Psychiatric effects: Insomnia (2135%), dry mouth (3044%), and mood changes in some patients Gastrointestinal: Nausea, diarrhea, and constipation at rates above placebo The cardiovascular signal particularly the heart rate increase would become the central obstacle in tesofensine's regulatory path
I've been told that this is a very dangerous job
Dual GIP & GLP-1 Agonists While Single GLP-1 RAs focus on one incretin pathway (the GLP-1 pathway), Dual GIP and GLP-1 agonists double down by also acting on another pathway involved in glucose regulation and energy balance
Figure 3 Neuroplasticity Effect The adult brain can adapt to internal and external stressors through structural plasticity, and failed resilience is likely to cause depression and anxiety
Is the ideal cycle length different for fat loss versus muscle gain
Similarly, patients with active malignancy warrant careful consideration given theoretical concerns about angiogenic effects potentially affecting tumor growth, though preclinical evidence suggests context-dependent effects that may inhibit rather than promote tumor angiogenesis